Cargando…

The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors

PURPOSE: To determine if the radiomic features on CT can predict progression-free survival (PFS) in epidermal growth factor receptor (EGFR) mutant adenocarcinoma patients treated with first-line EGFR tyrosine kinase inhibitors (TKIs) and to identify the incremental value of radiomic features over co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hyungjin, Park, Chang Min, Keam, Bhumsuk, Park, Sang Joon, Kim, Miso, Kim, Tae Min, Kim, Dong-Wan, Heo, Dae Seog, Goo, Jin Mo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669442/ https://www.ncbi.nlm.nih.gov/pubmed/29099855 http://dx.doi.org/10.1371/journal.pone.0187500

Ejemplares similares

Targeting CD73 to Overcomes Resistance to First-Generation EGFR Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer
por: Kim, Miso, et al.
Publicado: (2023)

Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma
por: Kang, Minsu, et al.
Publicado: (2021)

The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy
por: Choi, Ji Young, et al.
Publicado: (2019)

Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non–Small Cell Lung Cancer
por: Lee, Chaelin, et al.
Publicado: (2022)

Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor
por: Park, Sehhoon, et al.
Publicado: (2018)

Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations
por: Park, Sehhoon, et al.
Publicado: (2015)

Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Keam, Bhumsuk, et al.
Publicado: (2014)

The Effect of Hospice Consultation on Aggressive Treatment of Lung Cancer
por: Yoo, Shin Hye, et al.
Publicado: (2018)

Generalization and representativeness of phase III immune checkpoint blockade trials in non‐small cell lung cancer
por: Yoo, Shin Hye, et al.
Publicado: (2018)

Costs and clinical outcomes of patients with diffuse large B-cell lymphoma in first remission: role of PET/CT surveillance
por: Suh, Koung Jin, et al.
Publicado: (2019)

The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase‐positive non‐small cell lung cancer
por: Heo, Ja Yoon, et al.
Publicado: (2019)

Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
por: Kim, Seulki, et al.
Publicado: (2019)

The antitumor activity of a novel GCN2 inhibitor in head and neck squamous cell carcinoma cell lines
por: Lee, Jeongjae, et al.
Publicado: (2022)

Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines
por: Park, Ji-Eun, et al.
Publicado: (2020)

Pretreatment neutrophil‐lymphocyte ratio is not a significant prognostic factor in epidermal growth factor receptor‐mutant non‐small cell lung cancer patients treated with tyrosine kinase inhibitors
por: Sim, Sung Hoon, et al.
Publicado: (2015)

The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis
por: Kim, Ryul, et al.
Publicado: (2016)

A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma
por: Kim, Miso, et al.
Publicado: (2018)

Blockade of CD47 enhances the antitumor effect of macrophages in renal cell carcinoma through trogocytosis
por: Park, Ha-Ram, et al.
Publicado: (2022)

Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity
por: Yoo, Shin Hye, et al.
Publicado: (2018)

Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer
por: Kim, Su-Jung, et al.
Publicado: (2019)

Impact of Reconstruction Algorithms on CT Radiomic Features of Pulmonary Tumors: Analysis of Intra- and Inter-Reader Variability and Inter-Reconstruction Algorithm Variability
por: Kim, Hyungjin, et al.
Publicado: (2016)

Difficulties Doctors Experience during Life-Sustaining Treatment Discussion after Enactment of the Life-Sustaining Treatment Decisions Act: A Cross-Sectional Study
por: Yoo, Shin Hye, et al.
Publicado: (2021)

Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer
por: Ock, Chan-Young, et al.
Publicado: (2019)

Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma
por: Park, Changhee, et al.
Publicado: (2020)

Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment
por: Oh, So Yeon, et al.
Publicado: (2021)

Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy
por: Kim, Miso, et al.
Publicado: (2015)

Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure
por: Cho, Kyoung Min, et al.
Publicado: (2015)

Cancer Treatment near the End-of-Life Becomes More Aggressive: Changes in Trend during 10 Years at a Single Institute
por: Choi, Younak, et al.
Publicado: (2015)

KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer
por: Park, Sehhoon, et al.
Publicado: (2017)

A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas
por: Kim, Miso, et al.
Publicado: (2021)

Temporal evolution of programmed death-ligand 1 expression in patients with non-small cell lung cancer
por: Nam, Chang Hyun, et al.
Publicado: (2021)

Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations
por: Park, Sehhoon, et al.
Publicado: (2016)

Hospice-Palliative Medicine as a Model of Value-Based Healthcare
por: Heo, Dae Seog, et al.
Publicado: (2022)

Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma
por: Kim, Ryul, et al.
Publicado: (2016)

Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer
por: Kim, Miso, et al.
Publicado: (2017)

Implication of the Life-Sustaining Treatment Decisions Act on End-of-Life Care for Korean Terminal Patients
por: Kim, Jung Sun, et al.
Publicado: (2020)

Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis
por: Park, Changhee, et al.
Publicado: (2019)

Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patients
por: Heo, Ja Yoon, et al.
Publicado: (2021)

Microscopic Invasions, Prognoses, and Recurrence Patterns of Stage I Adenocarcinomas Manifesting as Part-Solid Ground-Glass Nodules: Comparison With Adenocarcinomas Appearing as Solid Nodules After Matching Their Solid Parts’ Size
por: Hwang, Eui Jin, et al.
Publicado: (2016)

Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP
por: Cho, Kyoung Min, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_s4fsr198ilrfq005rva4ms80bv